Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 P.M. ET to Discuss Financial Results for Its Fiscal Third ...
July 18 2016 - 7:30AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal third quarter ended June 30, 2016 after the U.S. markets
close on August 8, 2016. Enanta management will host a conference
call at 4:30 p.m. ET to discuss these results and provide an update
on Enanta’s research and development pipeline.
Conference Call and Webcast InformationTo participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 7:30
p.m. Eastern time on August 8, 2016, through 11:59 p.m. Eastern
time on August 12, 2016 by dialing (855) 859-2056 from the U.S. or
(404) 537-3406 for international callers. The passcode for both the
live call and the replay is 46602812. A live audio webcast of the
call and replay can be accessed by visiting the “Calendar of
Events” section on the “Investors” page of Enanta’s website at
www.enanta.com.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta’s research and development is currently focused on four
disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV),
Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial
Virus (RSV).
Enanta has developed direct-acting-antiviral (DAA) inhibitors
designed for use against HCV. Enanta’s protease inhibitors,
developed through its collaboration with AbbVie, include
paritaprevir, which is contained in AbbVie’s marketed DAA regimens
for HCV, and ABT-493, Enanta’s second protease inhibitor, which
AbbVie is developing in phase 3 studies in combination with
ABT-530, AbbVie’s NS5A inhibitor. Enanta has also discovered a
cyclophilin inhibitor, EDP-494, a novel, host-targeting mechanism
for HCV, which is now in phase 1 clinical development, and EDP-305,
an FXR agonist, which Enanta plans to advance into clinical
development for NASH later in 2016. In addition, Enanta has early
lead candidates for HBV and RSV in preclinical testing. Please
visit www.enanta.com for more information on Enanta’s programs and
pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160718005100/en/
Investor Contact:Enanta Pharmaceuticals, Inc.Carol
Miceli, 617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024